Report Library
All ReportsDatamonitor Healthcare I&I Disease Analysis: Crohn's Disease
December 13, 2023
Over the next decade, all key marketed brands for CD will face patent expiry. Thus far, the European market has taken the brunt of biosimilar erosion, with earlier launches and more acceptance compared to other countries. In the US, biosimilars will face challenges in usurping branded anti-TNFs, with adalimumab biosimilars launched in 2023, substantial originator rebates, and exclusive contracting with payers. Over time, biosimilar penetration is anticipated to gain more momentum as international real-world evidence accumulates and long-term data support biosimilar efficacy and safety. This should allow physicians and patients to grow their confidence and familiarity with biosimilars and encourage uptake.
This Datamonitor Healthcare report contains a Disease Analysis module.
Indications Covered: |
Crohn's Disease
Inflammatory Bowel Disease (IBD) |